Stay updated with breaking news from Krish Krishnan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Krystal Biotech’s Vyjuvek is approved to treat recessive and dominant forms of dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. The redosable gene therapy, applied to the skin, delivers a gene that gets cells to produce collagen that DEB patients lack.
Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) and Krystal Biotech (NASDAQ:KRYS – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability. Volatility & Risk Cyclo Therapeutics has a beta of -0.41, […]
The first rub-on gene therapy shows how biotech companies are getting creative with how they deliver DNA fixes.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ERJFCUQHSBNADKPCY22S65YXSI.jpg)
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading.
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading. Patients with the rare dystrophic epidermolysis bullosa disorder suffer from open wounds, ca...